Journal of Clinical Oncology
Articles in this Issue
Accelerating national burden of pancreatic cancer in the United States: Contemporary real-world trends, demographic disparities, and exploratory ARIMA projections from a federated electronic health record network.
e16469 Background: Pancreatic cancer remains among the most lethal malignancies worldwide, with limited improvement in sur...
Pilot RCT to study the effect of chronotherapy on gefitinib plasma concentrations and adherence in lung cancer patients.
e15144 Background: Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases, with EGFR mutations dr...
Impact of genomic HLA class I allelic imbalance on enduring immunotherapy response in advanced non–small cell lung cancer.
8582 Background: Human leukocyte antigen class I (HLA-I) molecules are essential for neoantigen presentation and T cell re...
Trends and disparities in arrhythmia-related mortality among older adults with cancer in the United States (1999-2023).
e24008 Background: Arrhythmias, or irregular heart rhythms, are common in patients with cancer. They can result from the c...
Double lung transplantation in patients with metastatic lung-limited non–small cell lung carcinoma (NSCLC): A case series.
e20777 Background: The role of double lung transplantation (DLT) in patients with advanced bilateral lung-limited non-smal...
Observation versus maintenance PD-1 inhibitor therapy after clinical complete response in dMMR/MSI-H colorectal cancer managed with non-operative management: A multicentre cohort study.
3502 Background: Patients with mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) colorectal cancer...
Radical cystectomy vs bladder-sparing therapy in very high-risk non–muscle-invasive bladder cancer: Real-world 5-year outcomes and immune checkpoint inhibitor–based substrategy analysis.
e16610 Background: While early radical cystectomy (RC) is recommended by contemporary guidelines for very high-risk non–mu...
Vessel branching patterns quantified by artificial intelligence as a novel prognostic biomarker in advanced renal cell carcinoma: A post-hoc analysis of the CM914 trial.
4523 Background: Current adjuvant risk stratification in renal cell carcinoma (RCC) relies primarily on TNM-staging. Howev...
A comprehensive evaluation of the effectiveness of the Geriatric 8 screening tool in Japanese patients with non–small cell lung cancer: Results from the ENSURE-GA study, a cluster-randomized phase III clinical trial.
8599 Background: The Geriatric 8 (G8) is a widely utilized screening tool globally for assessing functional status in elde...
Effect of BMI and BMI and Charlson Comorbidity Index on mortality in pancreatic cancer: A single-institution study.
e16473 Background: Pancreatic cancer is an extremely aggressive disease known for its poor outcomes. There are limited pro...
Recent trends in utilization of outpatient medical oncology services.
11101 Background: Health systems face escalating demand from rising cancer incidence and treatment complexity. Effective h...
SARC046: A phase II trial of nab-sirolimus in patients with progressing or symptomatic epithelioid hemangioendothelioma.
TPS11592 Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma with about 120 cases diagnos...
Myoepithelial carcinoma: Defining natural history and therapeutic outcomes in a rare malignancy.
e18143 Background: Myoepithelial carcinoma (MEC) is a neoplasm derived from myoepithelial cells and characterized by an in...
Development and internal validation of a web-based risk assessment tool for chemotherapy-induced peripheral neuropathy: A retrospective cohort study.
e24154 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting toxicity that can impair q...
Circulating tumor deoxyribonucleic acid (DNA) and treatment outcomes of gastroesophageal cancer: A systematic review and meta-analysis.
4185 Background: Gastroesophageal tumors are some of the most highly prevalent cancers worldwide. Despite the high prevale...
The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck carcinoma (HNSCC).
6058 Background: Ficerafusp alfa is the first and only bifunctional EGFR-directed antibody designed to trap TGF-β, enablin...
Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).
4584 Background: EVP is the preferred frontline regimen in pts with aUC. Despite initial response to treatment, many pts t...
Spatial transcriptomic profiling of the tumor microenvironment associated with sunitinib response in metastatic renal cell carcinoma.
3119 Background: Metastatic clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous clinical outcomes, and limited...
Routine prognostic blood tests to compare survival outcomes with low-dose therapy in treatment-naïve and resistant advanced pancreatic cancer.
e16349 Background: Patients with advanced pancreatic cancer (APC) have limited effective treatment options and substantial...
Practical prognostic tool for personalising first-line alectinib in ALK-positive NSCLC: A real-world model integrating neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and eosinophil count.
e20743 Background: Despite the efficacy of first-line alectinib in anaplastic lymphoma kinase (ALK)-positive non-small cel...
Real-world effectiveness of sacituzumab govitecan (SG) versus trastuzumab deruxtecan (T-DXd) in HER2-negative (HER2-) metastatic breast cancer (MBC) in China: A propensity-score–matched study.
3034 Background: SG and T-DXd are both antibody-drug conjugates (ADC) approved in China for HER2- MBC patients. However, d...
Effect of dose-escalated WBRT on survival in NSCLC leptomeningeal metastases: A multimodal analysis of local and systemic therapies.
e14021 Background: Leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) carry a dismal prognosis. Modern...
Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib for hepatocellular carcinoma with solitary large tumor and microvascular invasion: A prospective, single-arm, phase II trial.
e16252 Background: Hepatocellular carcinoma (HCC) with a solitary large tumor (≥ 5 cm) and microvascular invasion (MVI) is...
Phase II randomized trial of radiotherapy with pembrolizumab vs. cisplatin for unfavorable-risk p16+ head and neck squamous cell carcinoma (KEYCHAIN).
6016 Background: Standard chemoradiation (CRT) for unfavorable risk p16+ head and neck squamous cell carcinoma (HNSCC) is...
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage III acral melanoma: Updated CAP 03-NEO trial results and external control comparison.
9571 Background: SWOG1801 and NADINA trials suggested that neoadjuvant therapy may provide greater benefits than adjuvant...